Agatsa Software Pvt Ltd

Agatsa Software Pvt Ltd is a healthcare technology company focused on innovative cardiac health monitoring solutions, creating accessible ECG devices for diverse users, from healthcare professionals to fitness enthusiasts. Founded in 2014 and headquartered in Noida, India, Agatsa Software Pvt Ltd specializes in cardiac health monitoring solutions. The company was co-founded by Neha Rastogi and Rahul Rastogi. Agatsa has successfully completed a total of 10 deals, with the most recent funding round occurring on September 9, 2022, where it raised INR 20.

28 million. The current company valuation stands at INR 602. 41 million. Agatsa specializes in developing innovative cardiac health monitoring solutions, primarily through their flagship products, the SanketLife ECG devices.

These include SanketLife 2. 0, a touch-based 12-lead ECG monitor providing real-time heart activity analysis, and SanketLife ProPlus, which functions as both a touch-based and lead-based ECG device. The products are designed for ease of use, requiring minimal setup and providing instant access to detailed ECG reports via the associated SanketLife app. The primary markets for Agatsa's products include India and potential expansion into the United States and Europe, where demand for accessible cardiac health monitoring is growing.

In the most recent financial year, Agatsa reported a revenue of INR 138,251. 1, while experiencing an EBITDA loss of INR 1,367,363. 7. The company generates revenue primarily through direct sales of its medical devices, targeting individual consumers and healthcare professionals.

Agatsa's transaction structure is direct-to-consumer, with products available at fixed prices, such as the EasyTouch Plus device priced at INR 5,999 and ZLU sleep aid priced at INR 3,999. Additionally, Agatsa is pursuing B2B partnerships to integrate their technology into broader health platforms. Agatsa Software Pvt Ltd plans to leverage the recent funding of INR 20. 28 million raised in September 2022 to enhance product development and expand market reach.

The company is designing new products aimed at improving cardiac health monitoring technology and intends to launch these in the next 12-18 months. Furthermore, Agatsa aims to penetrate new geographic markets, specifically targeting the United States and Europe by the end of 2024, to capitalize on the increasing demand for accessible cardiac health solutions.